Royalty Pharma (RPRX) return on equity (ROE)

Return on equity · fiscal 2025
11.9%

Royalty Pharma (RPRX) earned a return on equity of 11.9% in fiscal 2025 (the year ended December 31, 2025). That is 0.5 percentage points lower than the 12.4% of fiscal 2024. Figures as of 17 Nov 2026, 21:36 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
11.9%
Change on fiscal 2024
−0.5 pts
Highest on record
38.2%fiscal 2019
Lowest on record
0.8%fiscal 2022
Fiscal years on record
82018–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Royalty Pharma return on equity (ROE), in more detail

Across the 8 fiscal years on record (2018–2025), the highest was 38.2% in fiscal 2019 and the lowest 0.8% in fiscal 2022. The fiscal 2025 figure is higher than in 43% of the 7 earlier fiscal years on record, whose median is 12.4%.

History · 8 fiscal years

Return on equity by fiscal year

Royalty Pharma return on equity (ROE), year by year

Royalty Pharma (RPRX) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
202511.9% 0.5 pts down
202412.4% 5.0 pts down
202317.4% 16.6 pts up
20220.8% 5.3 pts down
20216.0% 3.8 pts down
20209.9% 28.4 pts down
201938.2% 8.0 pts up
201830.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Royalty Pharma and comparable companies
CompanyReturn on equityFiscal year
IQVIA Holdings IQV20.9%2025
Revolution Medicines RVMD-69.3%2025
Royalty Pharma RPRX11.9%2025
Biogen BIIB7.1%2025
GE HealthCare Technologies GEHC20.1%2025
Alcon ALC4.4%2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on RPRX

Royalty Pharma, figure by figure

Royalty Pharma (RPRX) overview: price, valuation and scorecardAll health care companies by market value

Royalty Pharma return on equity (ROE): questions and answers

What is Royalty Pharma's return on equity?

Royalty Pharma (RPRX) earned a return on equity of 11.9% in fiscal 2025 (the year ended December 31, 2025). That is 0.5 percentage points lower than the 12.4% of fiscal 2024.

Is Royalty Pharma's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 43% of the 7 earlier fiscal years on record, whose median is 12.4%.

What are the highest and lowest return on equity figures on record for Royalty Pharma?

Across the 8 fiscal years on record (2018–2025), the highest was 38.2% in fiscal 2019 and the lowest 0.8% in fiscal 2022.

How is Royalty Pharma's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Royalty Pharma (RPRX) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/RPRX/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.